Study aim | Carnitine(s) supplementation (dose and duration) | Study design/Subjects | Outcomes relevant to reproduction | Reference |
---|---|---|---|---|
Human Studies | ||||
Single center, prospective study to evaluate whether ALC modulates opiatergic pathway in a group of patients with stress-induced amenorrhea | 1 g/day ALC orally for 16 weeks | 24 patients (aged 21–32 years) with FHA for the last 6 months were subdivided into 2 groups: Group A (hypogonadotropic patients, plasma LH levels ≤3 mIU/ml, n = 16) Group B (normogonadotropic patients, plasma LH levels > 3 mIU/ml, n = 8) | • ALC administration significantly modulates GnRH and LH secretion in hypothalamic amenorrhea in hypogonadotropic patients • ALC probably affects neuroendocrine control of gonadotropin secretion by modulating opiatergic control of GnRH-LH secretion • Data support the use of ALC as a therapeutic drug for stress-induced reproductive disorders with low LH levels or hypogonadotropic condition | [17] |
Single center, double blinded, randomized controlled clinical trial to evaluate the effectiveness of LC on improving the ovulation and pregnancy rates as well as adverse metabolic indices in clomiphene-resistant PCOS women | 3 g/day LC orally from day three until day seven of the cycle | 170 clomiphene resistant PCOS women (aged less than 35 years) were randomly allocated into 2 groups: Group A (n = 85) received 250 mg clomiphene citrate plus LC Group B (n = 85) received 250 mg clomiphene citrate with placebo | • The combination of LC and CC significantly improved both the ovulation and the pregnancy rates in clomiphene-resistant PCOS women • The number of stimulated follicles reaching ≥17 mm diameter was significantly higher in Group A as compared to Group B • Endometrium at the time of hCG administration was significantly thicker in Group A • Serum E2, on the day of hCG administration, was significantly higher in the LC group • Pregnancy occurred in 42/85 cycles in Group A (54.5%) and 5/85 cycles in Group B (5.8%) and the difference was statistically significant. • The miscarriage rate was lower in Group A (2/85; 2.3%) than in Group B (4/85; 4.7%) (p = 0.67) | [11] |
Before-after clinical trial to examine the effect of adding LC to PCOS patients who were resistant to clomiphene citrate and gonadotropin | 2 g LC orally every 12 h, given from the third day of treatment with clomiphene citrate and gonadotropin until the hCG injection | 50 PCOS patients (aged 20–35 years) either received LC or did not receive LC | • LC-treated women experienced the growth of dominant follicles (64%, 32/50 therapeutic cycles) and displayed a positive pregnancy test (20%, 10/50 therapeutic cycles) • LC-supplemented women had increased left ovarian follicle size compared to those without LC, however right ovarian follicle size was not significantly different between both groups • LC supplementation increased the mean endometrial thickness compared to those without LC. | [18] |
Prospective, randomized, double-blind, placebo-controlled trial to determine the effects of oral LC supplementation on weight loss, and glycemic and lipid profiles in women with PCOS | 250 mg LC orally for 12 weeks | 60 overweight PCOS (aged 18–40 years) were randomized to receive either LC (n = 30) or placebo (n = 30) | • LC supplementation reduced body weight, body mass index, waist circumference and hip circumference and improved glycemic control in PCOS patients compared with placebo. • LC supplementation did not affect lipid profiles or free testosterone levels compared with placebo | [12] |
Oral LC supplementation on mental health and biomarkers of OS in women with PCOS | 250 mg LC for 12 weeks | 60 patients: randomized, double-blind, placebo-controlled study | • LC supplementation improved general and mental health parameters • LC supplementation improved TAC, MDA/TAC ratio and decreased lipid peroxidation | [40] |
Animal Studies | ||||
LC supplementation on endometriosis in BALB/c mice | 25 mg/ml/d LC for 7 days | Young female BALB/c mice of 4–8 weeks of age | • Increased concentration of LC in serum • Decreased levels of IFN-γ, TNF-α, IL-6, IL-2 | [19] |
LC on reproductive hormones and organs of pregnant mice | 0.5 and 1.0 mg/kg LC from day-1 until parturition | Female Swiss albino mice of 12–14 weeks of age | • Significantly increased FSH, LH and estradiol levels • Increased litter size, weight of reproductive organs and thickness of endometrium | [42] |
ALC on HPG axis of female Sprague-Dawley rats | 50 mg/kg/d ALC for 2 consecutive estrous cycles | Female Sprague-Dawley rats of 3 months of age | Improved hormonal secretions through HPG axis: increased GnRH, LH, estradiol and progesterone levels | [16] |
LC on OS parameters in oophorectomized rats | 100Â mg/kg/d LCÂ during post-castration day-21 to -35 (14 consecutive days) | Female adult Wistar rats | Decreased MDA, and NO levels, and improved TAC and OS index | [49] |
Reproductive performance of sows on LC-supplementation | 125 mg/d LC (pregnancy), 250 mg/d LC (lactation) | 300 sows (Leicoma) | Improved litter size and piglets' body weight gain, decreased number of stillborn piglets | [51] |
LC in gestating sow diet on fetal development | 50Â ppm in diet for 3 reproductive cycles, until day-110 of gestation | 232 gestating sows | Increased leanness and muscle density in offspring | [52] |
Dietary LC on laying hen performance and egg quality | 500Â mg/kg LCÂ diet for 84Â days | 180 Isabrown laying hens of 27-weeks of age | Improved egg quality parameters including albumin content | [50] |
LC on reproductive traits of white leghorns | 125Â ppm LCÂ until 37-week of age | 720 White leghorns | Improved total lipid and LC content in yolk | [43] |
LC in cows during transition and high lactation period | 2Â g/d LCÂ for 5Â weeks | 262 dairy cows (German Holstein) | Improved metabolic status during lactation period, increased milk protein content | [53] |